Page 7 - Nasdaq Fdmt News Today

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) is one of 264 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare 4D Molecular Therapeutics to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations. Institutional & […]

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) and Axcella Health (NASDAQ:AXLA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Institutional and Insider Ownership 76.6% of 4D Molecular […]

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. […]

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses […]

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) shares gapped up prior to trading on Tuesday . The stock had previously closed at $15.99, but opened at $16.58. 4D Molecular Therapeutics shares last traded at $15.66, with a volume of 167 shares traded. Several research firms recently weighed in on FDMT. SVB Leerink began coverage […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) – Investment analysts at SVB Leerink issued their FY2023 EPS estimates for 4D Molecular Therapeutics in a research report issued to clients and investors on Tuesday, March 29th. SVB Leerink analyst M. Foroohar anticipates that the company will post earnings per share of ($2.58) for the year. […]

4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) announced its quarterly earnings results on Monday. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.01, Fidelity Earnings reports. Shares of NASDAQ FDMT traded down $0.86 during trading hours on Wednesday, hitting $15.49. 157,562 shares of the company’s stock […]

EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing...

EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the...